Loading company…
Stockholm biopharma developing therapies that target the angiotensin II type 2 receptor, led by buloxibutid.
Vicore Pharma Holding AB develops therapies targeting the angiotensin II type 2 (AT2) receptor. Its lead candidate, buloxibutid (C21), is an oral small molecule in phase 2a development for idiopathic pulmonary fibrosis, and its Almee digital therapeutic has FDA Breakthrough Device Designation. Founded in 2009 in Stockholm, Sweden, it raised SEK 102.000 mn in its latest LP Direct round, with Sanofi among investors, and has executed four deals. All VC investors have exited their stake.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in